Cannabist Company Holdings (CBST) AI Stock Analysis

• Market Cap: C$227.80M
• Dividend Yield: N/A
• Average Volume (3M): 0.00
• Price to Earnings (P/E): ―
• Beta (1Y): N/A
• Revenue Growth: -26.73%
• EPS Growth: -32.33%
• Country: CA
• Employees: 1,681
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.04
• Shares Outstanding: 535,360,840
• 10 Day Avg. Volume: 0
• 30 Day Avg. Volume: 0
• PEG Ratio: <0.01
• Price to Book (P/B): -1.06
• Price to Sales (P/S): 0.07
• P/FCF Ratio: -1.05
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 37 Underperform
• Price Target: C$0.52 ▼(-6.43% Downside)

Cannabist Company Holdings is facing severe financial difficulties, with declining revenues, high leverage, and negative equity. The technical analysis indicates an overbought condition without clear momentum, and the valuation reflects unprofitability. These factors contribute to a low overall stock score.

Positive Factors

Product Diversity

A diverse product range allows Cannabist Company Holdings to cater to various consumer preferences, enhancing market reach and resilience against market fluctuations.

Strategic Partnerships

Strategic partnerships can strengthen supply chain reliability and expand product offerings, supporting long-term growth and competitive positioning.

Brand Presence

A strong brand presence can enhance customer loyalty and market share, providing a durable competitive advantage in a rapidly evolving industry.

Negative Factors

Declining Revenue

Declining revenues indicate challenges in market demand or competitive pressures, which can undermine long-term financial stability and growth prospects.

High Leverage

High leverage increases financial risk and limits flexibility, potentially impacting the company's ability to invest in growth opportunities or weather economic downturns.

Negative Profit Margins

Negative profit margins highlight operational inefficiencies and the need for cost management, which can hinder long-term profitability and shareholder value.

Cannabist Company Holdings Business Overview & Revenue Model

Company Description

The Cannabist Company Holdings Inc. engages in the cultivation, manufacture, and provision of cannabis products and related services in the United States and internationally. The company offers spanning flower, edibles, oils, and tablets under the Seed & Strain, Triple Seven, Hedy, gLeaf, Classix, Press, and Amber brand names. It holds licenses in 17 jurisdictions in the United States. The company was formerly known as Columbia Care Inc. and changed its name to The Cannabist Company Holdings Inc. in September 2023. The company was founded in 2012 and is headquartered in New York, New York.

How the Company Makes Money

Cannabist Company Holdings generates revenue primarily through the sale of its cannabis products in both medical and recreational markets. The company operates retail dispensaries, which serve as direct sales points to consumers, and also engages in wholesale distribution to other licensed retailers. Key revenue streams include the sale of dried flower, concentrates, edibles, and branded merchandise. Additionally, CBST may benefit from strategic partnerships with local growers and suppliers to enhance its product offerings and ensure a steady supply chain. Regulatory compliance and a strong brand presence in evolving markets further contribute to its earnings.

Cannabist Company Holdings Financial Statement Overview

Summary

Cannabist Company Holdings faces significant financial challenges across all verticals. The income statement shows declining revenues and persistent losses, while the balance sheet is burdened with high debt and negative equity. Cash flow issues further exacerbate the situation, with negative operating and free cash flows. The company needs to address these financial weaknesses to improve its financial health and stability.

Income Statement

The income statement reveals significant challenges, with declining revenue growth at -9.17% TTM and negative net profit margins consistently over the years. The gross profit margin has slightly decreased to 35.03% TTM, indicating some pressure on profitability. The company has struggled with negative EBIT and EBITDA margins, reflecting operational inefficiencies.

Balance Sheet

The balance sheet shows a concerning financial structure with a negative stockholders' equity of -$137.97 million TTM, leading to an unsustainable debt-to-equity ratio of -7.66. The return on equity is positive at 10.11% TTM, but this is due to the negative equity, which is not a healthy sign. The equity ratio is negative, indicating liabilities exceed assets.

Cash Flow

Cash flow analysis indicates negative operating cash flow and free cash flow, with a declining free cash flow growth rate of -18.86% TTM. The operating cash flow to net income ratio is negative, suggesting cash flow issues. However, the free cash flow to net income ratio is above 1, indicating some ability to cover net losses with free cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	349.84M	458.72M	511.33M	491.31M	456.03M	188.99M
Gross Profit	103.25M	168.30M	179.97M	136.13M	146.92M	52.68M
EBITDA	-49.43M	28.61M	-51.30M	-282.36M	-63.14M	-115.66M
Net Income	-178.96M	-105.89M	-175.71M	-399.52M	-141.84M	-100.85M
Balance Sheet
Total Assets	536.51M	696.17M	823.11M	994.28M	1.37B	727.53M
Cash, Cash Equivalents and Short-Term Investments	17.76M	33.61M	36.91M	48.13M	82.09M	61.11M
Total Debt	443.05M	478.42M	546.32M	566.97M	420.75M	295.21M
Total Liabilities	689.46M	726.23M	757.76M	787.47M	824.57M	440.58M
Stockholders Equity	-151.68M	-28.69M	66.53M	213.19M	570.62M	306.82M
Cash Flow
Free Cash Flow	-37.16M	-29.21M	-2.50M	-179.70M	-132.64M	-97.42M
Operating Cash Flow	-31.37M	-23.38M	7.47M	-106.99M	-518.40K	-52.27M
Investing Cash Flow	36.15M	30.98M	-3.50M	-72.34M	-189.67M	-24.02M
Financing Cash Flow	-18.95M	-9.00M	-14.12M	147.59M	200.66M	90.00M

Cannabist Company Holdings Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.56
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Neutral
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:CBST, the sentiment is Negative. The current price of 0.56 is below the 20-day moving average (MA) of 0.56, above the 50-day MA of 0.56, and below the 200-day MA of 0.56, indicating a neutral trend. The MACD of >-0.01 indicates Neutral momentum. The RSI at 100.00 is Negative, neither overbought nor oversold. The STOCH value of 66.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:CBST.

Cannabist Company Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LOVE	73 Outperform	C$173.66M	12.87	13.39%	―	30.64%	101.12%
XLY	67 Neutral	C$198.22M	4.08	31.46%	―	27.38%	―
TRBR	56 Neutral	C$172.47M	-9.66	-184.37%	―	40.28%	26.23%
GRIN	52 Neutral	C$149.75M	16.13	15.32%	―	-18.30%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
JUSH	47 Neutral	C$159.32M	-1.83	―	―	3.17%	-24.07%
CBST	37 Underperform	C$227.80M	-1.07	―	―	-26.73%	-32.33%

Cannabist Company Holdings Corporate Events

Cannabist Company Sells Virginia Assets to Curaleaf for $110 Million

The Cannabist Company Holdings Inc. has announced an agreement to sell its Virginia-based cannabis operations to Curaleaf Holdings Inc. for $110 million. This transaction is part of a strategic review by the company’s board to address operational and financial challenges amid regulatory uncertainties in the cannabis industry. The sale includes five active retail locations, one in development, and a substantial cultivation and production facility. The agreement features a mix of cash payments and a promissory note, with provisions for adjustments based on various financial metrics. The transaction is subject to regulatory approvals and other conditions, with a go-shop period allowing the company to explore alternative proposals.

The most recent analyst rating on (TSE:CBST) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Cannabist Company Holdings stock, see the TSE:CBST Stock Forecast page.

The Cannabist Company to Announce Q3 2025 Financial Results

The Cannabist Company announced it will release its third-quarter 2025 financial results on November 10, 2025, after the U.S. financial markets close. This announcement is significant as it provides stakeholders with insights into the company’s financial health and operational performance, potentially impacting its market positioning and investor confidence.

The most recent analyst rating on (TSE:CBST) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Cannabist Company Holdings stock, see the TSE:CBST Stock Forecast page.